<DOC>
	<DOCNO>NCT02261506</DOCNO>
	<brief_summary>Bacteremia lead cause mortality morbidity critically ill adult . Although bacteria bloodstream ( bacteremia ) may arise variable infectious focus ( commonly central vascular catheter relate , lung , urinary tract , intra-abdominal , skin soft tissue source ) , high attendant morbidity mortality bacteremia , patient collectively represent critically important group study . The consequence excessive antimicrobial use individual patient , range rash , gastrointestinal upset diarrhea , anaphylaxis , neutropenia , renal failure , toxic epidermal necrolysis , death , mark increase ICU hospital drug cost . One particularly concern complication , Clostridium difficile infection , increase incidence severity past decade . Much burden could prevent reduction unnecessary antibiotic use . Another major consequence excessive antibiotic use antimicrobial resistance . Antibiotic resistance concern patient receive antibiotic , also neighbour patient ICU , well future patient ICU hospital large - patient-to-patient transmission , environmental contamination . No previous randomize controlled trial directly compare short versus long duration antimicrobial treatment patient . The investigator conduct multi-center randomize concealed allocation trial short duration ( 7 day ) versus long duration ( 14 day ) antibiotic treatment critically ill patient bacteremia admit ICU . Eligible , patient randomize either 7 day 14 day adequate antimicrobial treatment . The selection type , dose route antibiotic discretion treat physician , duration treatment ( 7 versus 14 day ) determine randomization group . The randomization assignment communicate study research coordinator , study critical care infectious disease investigator clinician day 8 . The primary outcome main trial 90-day mortality . The study initiate Sunnybrook Health Sciences Centre Toronto , Ontario , roll second site Kingston General Hospital Kingston , Ontario . These site sufficient meet sample size goal pilot RCT , additional fund obtain investigator also roll Canadian ICUs list . The goal add additional site increase generalizability finding respect trial feasibility</brief_summary>
	<brief_title>Bacteremia Antibiotic Length Actually Needed Clinical Effectiveness : A Pilot RCT</brief_title>
	<detailed_description />
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>Patient ICU time blood culture result report positive AND Patient positive blood culture pathogenic bacteria . Patient already enrol trial Patient severe immune system compromise , define : absolute neutrophil count &lt; 0.5x109/L ; receive immunosuppressive treatment solid organ bone marrow stem cell transplant Patient syndrome welldefined requirement prolonged treatment : infective endocarditis osteomyelitis/septic arthritis undrainable/undrained abscess unremovable/unremoved prostheticassociated infection Patient single positive blood culture common contaminant organism accord Clinical Laboratory &amp; Standards Institute ( CLSI ) Guidelines : coagulase negative staphylococci ; Bacillus spp . ; Corynebacterium spp . ; Propionobacterium spp . ; Aerococcus spp . ; Micrococcus spp . Patient positive blood culture Staphylococcus aureus . Patient positive blood culture Candida spp . fungal specie .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Intensive care</keyword>
	<keyword>bacteremia</keyword>
	<keyword>bloodstream infection</keyword>
	<keyword>antimicrobial</keyword>
	<keyword>mortality</keyword>
	<keyword>antimicrobial stewardship</keyword>
</DOC>